Management of Early Stage Chronic Myeloid Leukemia: State-of-the-art Approach and Future Perspectives

Author(s): Federica Galaverna, Chiara Ghiggi, Fabio Guolo, Germana Beltrami, Clara Dellepiane, Livia Giannoni, Andrea Carella, Angelo M. Carella

Journal Name: Current Cancer Drug Targets

Volume 13 , Issue 7 , 2013

Become EABM
Become Reviewer
Call for Editor


Tyrosin Kinase inhibitors (TKI), have dramatically changed the natural history of chronic myeloid leukemia (CML) leading to an impressive increase in overall survival rates and allowing many CML patients to achieve a close-tonormal life expectancy. Unfortunately, there is growing evidence that these drugs are not curative, about 30-35% of the patients who receive imatinib become resistant or discontinue the drug because of side effects; moreover, 15% of all patients become resistant to all TKIs, a condition which represents the biggest challenge in CML treatment. Recent progresses in CML stem cell biology have identified new agents and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives and have highlighted key strategies for treating, and possibly curing, CML in the upcoming years.

Keywords: chronic myeloid leukemia, stem cell biology, tyrosine kinase inhibitors, new therapeutic strategies.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 31 August, 2013
Page: [749 - 754]
Pages: 6
DOI: 10.2174/15680096113139990087
Price: $65

Article Metrics

PDF: 9